ES2177527T3 - Uso de un inhibidor de la transglutaminasa para el tratamiento de tejidos cicatriales. - Google Patents

Uso de un inhibidor de la transglutaminasa para el tratamiento de tejidos cicatriales.

Info

Publication number
ES2177527T3
ES2177527T3 ES92906696T ES92906696T ES2177527T3 ES 2177527 T3 ES2177527 T3 ES 2177527T3 ES 92906696 T ES92906696 T ES 92906696T ES 92906696 T ES92906696 T ES 92906696T ES 2177527 T3 ES2177527 T3 ES 2177527T3
Authority
ES
Spain
Prior art keywords
pct
transglutaminase inhibitor
cicatrial
fabrics
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92906696T
Other languages
English (en)
Inventor
Kenneth N Dolynchuk
John Michael Bowness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Original Assignee
University of Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manitoba filed Critical University of Manitoba
Application granted granted Critical
Publication of ES2177527T3 publication Critical patent/ES2177527T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

LA INVENCION SE REFIERE AL TRATAMIENTO TERAPEUTICO DE UN TEJIDO HIPERTROFICO MARCADO CON CICATRICES CON UNA COMPOSICION QUE CONTIENE UN INHIBIDOR DE LA TRANSGLUTAMINASA NO TOXICO, TAL COMO PUTRESCINA, O UNA SAL DE ADICION ACIDA FARMACEUTICAMENTE ACEPTABLE DEL MISMO, Y A UN PORTADOR O DILUYENTE FARMACEUTICAMENTE ACEPTABLE. TAMBIEN SE PRESENTA UN METODO CONVENIENTE PARA EL TRATAMIENTO DE TEJIDOS HIPERTROFICOS MARCADOS CON CICATRICES CON TALES COMPOSICIONES.
ES92906696T 1992-03-23 1992-03-23 Uso de un inhibidor de la transglutaminasa para el tratamiento de tejidos cicatriales. Expired - Lifetime ES2177527T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA1992/000123 WO1993018760A1 (en) 1992-03-23 1992-03-23 Use of transglutaminase inhibitor for the treatment of scar tissue

Publications (1)

Publication Number Publication Date
ES2177527T3 true ES2177527T3 (es) 2002-12-16

Family

ID=4172922

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92906696T Expired - Lifetime ES2177527T3 (es) 1992-03-23 1992-03-23 Uso de un inhibidor de la transglutaminasa para el tratamiento de tejidos cicatriales.

Country Status (10)

Country Link
US (1) US5885982A (es)
EP (1) EP0632723B1 (es)
AT (1) ATE218330T1 (es)
AU (1) AU674828B2 (es)
BR (1) BR9207109A (es)
CA (1) CA2132416C (es)
DE (1) DE69232629T2 (es)
DK (1) DK0632723T3 (es)
ES (1) ES2177527T3 (es)
WO (1) WO1993018760A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004245A1 (en) * 1996-07-25 1998-02-05 The Victoria University Of Manchester Use of transglutaminase modulators to promote wound healing
US6060471A (en) * 1998-01-21 2000-05-09 Styczynski; Peter Reduction of hair growth
JP3012923B2 (ja) * 1998-01-26 2000-02-28 新潟大学長 Ｃａｇリピート病の治療薬
CN1235559C (zh) * 1998-03-11 2006-01-11 株式会社创研 皮肤水分保持能力的改善剂
AU2006203098B2 (en) * 1998-03-11 2009-10-08 Kabushiki Kaisha Soken Skin conditioner
US20040067212A1 (en) 1998-03-11 2004-04-08 Kabushiki Kaisha Soken Skin conditioner
WO1999051213A2 (en) * 1998-04-03 1999-10-14 Theodore Toney Ilenchuk The use of polyamines in the treatment of dermatological symptoms
KR100876753B1 (ko) * 1999-09-07 2009-01-07 가부시끼가이샤 소껭 피부 건전화제
US6709458B2 (en) 2000-02-04 2004-03-23 Gary Karlin Michelson Expandable push-in arcuate interbody spinal fusion implant with tapered configuration during insertion
EP1645248B8 (en) * 2000-02-04 2010-06-16 Warsaw Orthopedic, Inc. Expandable interbody spinal fusion implant having pivotally attached blocker
US6500205B1 (en) 2000-04-19 2002-12-31 Gary K. Michelson Expandable threaded arcuate interbody spinal fusion implant with cylindrical configuration during insertion
US6716247B2 (en) 2000-02-04 2004-04-06 Gary K. Michelson Expandable push-in interbody spinal fusion implant
US6814756B1 (en) 2000-02-04 2004-11-09 Gary K. Michelson Expandable threaded arcuate interbody spinal fusion implant with lordotic configuration during insertion
US6808537B2 (en) 2000-07-07 2004-10-26 Gary Karlin Michelson Expandable implant with interlocking walls
US7118579B2 (en) * 2001-02-04 2006-10-10 Sdgi Holdings, Inc. Instrumentation for inserting an expandable interbody spinal fusion implant
WO2003013245A1 (en) 2001-08-07 2003-02-20 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
GB0515003D0 (en) * 2005-07-21 2005-08-31 Univ Aston Medical devices and coatings therefor
EP1866329B1 (en) * 2005-12-16 2010-05-26 National Cancer Center Peptides for inhibiting transglutaminase
US20110034556A1 (en) * 2007-11-27 2011-02-10 Kenneth Nicholis Dolynchuk Use of transglutaminase inhibitor in skin treatment
US20100316764A1 (en) * 2009-06-10 2010-12-16 Engrain, LLC Flour supplement compositions and methods for preparing wheat flour
US20190298688A1 (en) * 2016-11-21 2019-10-03 Vivier Canada Inc. Putrescine slow-release topical formulations
US20190314299A1 (en) * 2017-01-06 2019-10-17 Vivier Canada Inc. Putrescine topical barrier formulation
WO2019232644A1 (en) * 2018-06-08 2019-12-12 Vivier Canada Inc. Sterile topical saline putrescine formulation and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1588110A (en) * 1978-05-31 1981-04-15 Geistlich Soehne Ag Pharmaceutical compositions for the treatment of scars
US4618490A (en) * 1980-06-06 1986-10-21 Marco Peter T De Method of treatment of animal and human tissues damaged by burns and frank visible gangrene
US4444787A (en) * 1981-07-06 1984-04-24 Board Of Regents, University Of Texas Ophthalmic topical use of collagen cross-linking inhibitors
US4428939A (en) * 1981-10-16 1984-01-31 Prockop Darwin J Collagen inhibiting compositions and processes for manufacturing and using same
US4507321A (en) * 1982-02-17 1985-03-26 The Research Foundation Of State University Of New York Epithelial cell growth regulating composition containing polyamines and a method of using same
US4485088A (en) * 1982-03-26 1984-11-27 Bio-Products, Inc. Method of treatment of fibrotic lesions by topical administration of lathyrogenic drugs
US4929630A (en) * 1986-03-14 1990-05-29 Syntex (U.S.A.) Inc. Transglutaminase inhibitors
US4694021A (en) * 1986-05-05 1987-09-15 Schweiger Raymond H Method for topical treatment of scar tissue
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
US4970297A (en) * 1987-03-13 1990-11-13 Syntex (U.S.A.) Inc. Transglutaminase inhibitors
US4968713A (en) * 1989-07-31 1990-11-06 Merck & Co., Inc. Certain imidazole compounds as transglutaminase inhibitors
US5132119A (en) * 1989-07-31 1992-07-21 Massachusetts Institute Of Technology Treatment of hypertrophic wound healing disorders with calcium channel blockers
US4997854A (en) * 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US5124358A (en) * 1990-01-16 1992-06-23 The Board Of Reagents The University Of Texas System Effect of transglutaminase inhibition on microfilariae development and macrofilariae viability
US5324508A (en) * 1990-06-11 1994-06-28 The Curators Of The University Of Missouri Method for decreasing the formation of scar tissue using a purified mammalian monokine product
US5120322A (en) * 1990-06-13 1992-06-09 Lathrotec, Inc. Method and apparatus for treatment of fibrotic lesions
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma

Also Published As

Publication number Publication date
EP0632723B1 (en) 2002-06-05
BR9207109A (pt) 1995-12-12
CA2132416A1 (en) 1993-09-30
CA2132416C (en) 2001-03-06
WO1993018760A1 (en) 1993-09-30
DK0632723T3 (da) 2002-09-09
EP0632723A1 (en) 1995-01-11
ATE218330T1 (de) 2002-06-15
DE69232629T2 (de) 2003-01-30
AU674828B2 (en) 1997-01-16
US5885982A (en) 1999-03-23
DE69232629D1 (de) 2002-07-11
AU1544892A (en) 1993-10-21

Similar Documents

Publication Publication Date Title
ES2177527T3 (es) Uso de un inhibidor de la transglutaminasa para el tratamiento de tejidos cicatriales.
ATE184776T1 (de) Biokompatibles implantat für die zeitliche abstimmung der ovulation von stuten
ES2123135T3 (es) Aparato y metodo para la aplicacion local de material polimerico a tejido.
DE69327845D1 (de) Behandlung von empfindlichen zähnen
CA2178728A1 (en) Skin tanning compositions
ATE331521T1 (de) Behandlung von schmerzen
FI971974A0 (fi) Tienopyridiini- tai tienopyrimidiinijohdannaiset ja niiden käyttö
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
DE69332713D1 (de) Verwendung von Histamine-2 Agonisten zur Behandlung sexueller Funktionsstörungen
EP0646007A4 (es)
GB2295088B (en) Control of hair growth
ATE154235T1 (de) Kosmetische oder pharmazeutische zusammensetzungen zur topischen anwendung die deacylierten glycerophospholipide enthalten
DK0914078T3 (da) Anvendelse af L-lysin til behandling af hårtab
NO985116L (no) Sammensetning som omfatter en KATP kanalhemmer for anvendelse i behandling av hemoragisk sjokk
DE60315238D1 (de) Verwendung eines Assoziates aus synergistischen Kalziumkanalblocker-Agentien zur Vermeidung oder Behandlung von Falten und feinen Linien
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
BR9508406A (pt) Uso de um composto e método para o tratamento e/ou profilaxia em mamíferos
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
ATE203162T1 (de) Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one
ATE245980T1 (de) Verwendung eines pyruvatdehydrogenaseaktivators zur behandlung der ischämie in gliedern
ATE137407T1 (de) Behandlung von intraocularem druck mit einer synergistischen kombination
ES2157984T3 (es) Utilizacion de 4'-yodo-4'-desoxidoxorrubicina para el tratamiento de la amidoidosis.
DE69724112D1 (de) Peptidverbindungen mit mmp- und tnf-hemmender wirkung